NEW YORK (GenomeWeb) – Quanterix has raised $46 million in Series D funding from new and existing investors.
Three new investors — Trinitas Capital, Cormorant Asset Management, and Arch Overage Fund — led the round with continued participation from existing investors Arch Venture Partners, Bain Capital Ventures, Tufts University, and Quanterix scientific founder David Walt. Hercules Capital also participated in the round.
In a statement, Lexington, Massachusetts-based Quanterix said it would use the proceeds to develop desktop instruments, expand its assay menu for protein and nucleic acid biomarkers, and build global sales. Proceeds will also be used for studies to demonstrate potential applications for Quanterix's single-molecule array technology in drug development, personalized medicine, and diagnostics.
The firm added that it has seen six consecutive quarters of 100 percent growth and is aiming to offer 60 assays by the end of the year. It also intends to ramp up its commercial channel to drive further global expansion, following its move into the Asia Pacific region earlier this year.